drugset
drugset / Trial / NCT00946387

To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Fasting Conditions

NCT00946387 ↗

Phase 1 Completed 26 enrolled Sandoz
RandomizedSingle-groupOpen-labelTreatment

Summary

To demonstrate the relative bioavailability study of Ondansetron HCl 24 mg tablets under fasting conditions.

Timeline

Start
2004-09
Primary completion
2004-09
Completion
2004-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Ondansetron Other / unclassified 24 mg —

Indications

No indication recorded.